Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
ST. LOUIS, Feb. 08, 2016 -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday, February 22, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis fourth quarter and full year 2015 financial results conference call | ||||||
| When: | Monday, February 22nd at 4:30 p.m. Eastern Time (1:30 p.m. PT) | ||||||
| Dial In Number: | To access the live call, dial 888-417-8465 (US and Canada) or 719-325-2329 (International) and give the participant pass code 4685179. | ||||||
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com | ||||||
| Call Replay: | A replay of the call will be available approximately one hour following the end of the call through 7:30 p.m. ET on February 29, 2016. | ||||||
| Replay Numbers: | 888-203-1112 (US and Canada) | ||||||
| 719-457-0820 (International) | |||||||
| Replay passcode: 4685179 | |||||||
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
Press Contact: Martin Stammer Chief Financial Officer 314-678-6155 Investor Contact: Todd Kehrli / Jim Byers MKR Group, Inc. 323-468-2300 [email protected]
